July 6, 2017
Celgene and BeiGene join to fight cancer
Celgene Corporation and BeiGene have entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
July 6, 2017
Novartis updates label for psoriasis drug in EU
The Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Novartis’s Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.
July 5, 2017
Stada makes big board changes
STADA Arzneimittel AG has appointed Engelbert Coster Tjeenk Willink as Chief Executive Officer with immediate effect.
July 3, 2017
AstraZeneca completes two commercial rights deals, payments included in Q2 2017
AstraZeneca on Monday reported closing two different agreements for certain commercial rights for its drugs, in Europe and worldwide.
June 23, 2017
LEADER trial data included in Novo Nordisks Saxenda in Europe
Novo Nordisk got the right from the European Medicines Agency’s committee (EMA) to include data from the LEADER trial to Saxenda to the results from the trial showed the long-term effects of Victoza for type 2 diabetes and established cardiovascular disease patients.
June 19, 2017
New test may turn AZ’s Lynparza into precision drug for prostate cancer
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
June 19, 2017
Novartis’s division wins EC approval for its cancer drug
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.
June 12, 2017
Sanofi’s and Regeneron’s diabetes drug testing shows positive results
Sanofi and Regeneron Pharmaceuticals have reported positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes.
June 9, 2017
J&J receives final EC approval to acquire Actelion
Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.
June 9, 2017
Vertex Pharmaceuticals welcomes new independent board member
Vertex Pharmaceuticals has appointed Alan M. Garber, M.D., Ph.D. as an independent member of its board of directors.